A steady science day covering degraders, kinase structure, HDAC selectivity, hit-finding, AI screening QC, and ion-channel natural products, alongside a busy business day: one approval, one merger, a pricing deal, a startup launch, a financing round, and two trial setbacks.
2026-09-17 · ⚗️Cav3.1 T-type calcium channel — natural-product-derived allosteric modulators · Organic Letters (ACS)
- Five new natural products, hyreptaones A-E (1-5), were isolated from the plant Hypericum reptans, defining a novel class of 1,2-seco-bicyclic polyprenylated acylphloroglucinols (BPAPs).
- Compounds 1-3 are the first 1,2-seco-BPAPs shown to derive from rare 3,3-diisoprenylated BPAP precursors, while 4 and 5 feature an unusual spirocyclic 6/5/5 ring system formed by further cyclization of the 1,2-seco-BPAP core.
- Structures were established using spectroscopic analysis together with X-ray crystallography.
- All five compounds preferentially inhibited the Cav3.1 T-type calcium channel over other T-type channel subtypes, indicating isoform selectivity.
- Compounds 4 and 5 additionally showed state-dependent modulation of Cav3.1 gating, marking them as a new class of Cav3.1 allosteric modulators.
💡 PointsIsoform selectivity within the T-type family (Cav3.1 vs 3.2/3.3) is exactly what's been missing from this space — most T-type blockers I've seen are promiscuous pore-blockers with narrow therapeutic windows, so five compounds hitting Cav3.1 preferentially is worth a second look.
The state-dependent gating modulation in 4/5 is the more interesting story mechanistically: allosteric, conformation-selective action tends to buy better selectivity and fewer off-target liabilities than brute-force channel block.
That said, I'm skeptical this scaffold is a med-chem starting point rather than a probe — a spirocyclic 6/5/5 BPAP that needed X-ray to nail down stereochemistry screams synthetic bottleneck, and five compounds isolated from one plant is not a supply chain, it's a bottleneck waiting to happen.
I'd want SAR against simplified, truncated analogs before believing this is optimizable rather than just interesting.
1,2-seco-Bicyclic Polyprenylated Acylphloroglucinols as Isoform Selective Inhibitors of T-Type Calcium Channels ↗
2026-09-17 · ⚗️EGFR-targeted degrader-antibody conjugate (cetuximab-PROTAC; VHL/COX-2) · Journal of the American Chemical Society (ACS)
- Researchers built Ctx-ETAC, a degrader-antibody conjugate pairing the approved EGFR antibody cetuximab with an engineered PROTAC payload, attached via a bioorthogonal reaction at a defined, controlled ratio per antibody.
- Its PROTAC payload pairs an indomethacin-derived COX-2 ligand with a VHL-recruiting peptide via a cathepsin B-cleavable linker, releasing the degrader selectively inside EGFR-positive tumor cells and activated fibroblasts.
- Degrading COX-2 in both cell types substantially curtails extracellular vesicle secretion, severing a key tumor-stroma signaling channel and nudging fibroblasts toward a quiescent, less tumor-supportive state.
- In a lung cancer xenograft model, Ctx-ETAC outperformed cetuximab alone in restraining tumor growth without added systemic toxicity, supporting microenvironment-targeted degradation as a therapeutic strategy.
💡 PointsFinally, a DAC that isn't just "ADC with a cooler payload" — swapping a cytotoxin for a VHL-PROTAC means efficacy doesn't hinge on brute-force poisoning of every internalized antibody; you get catalytic, event-driven target destruction instead.
Smart target choice: COX-2 isn't the oncogenic driver, it's stromal plumbing. Cutting EV secretion to defuse tumor-fibroblast crosstalk instead of chasing EGFR resistance mutations directly is a genuinely different SAR logic than the usual "degrade the driver" playbook.
Chemistry-wise, nothing exotic — indomethacin-COX-2 ligand, VHL peptide, cathepsin B-cleavable linker, defined-DAR bioorthogonal attachment. That's the point: boringly tractable, which is exactly what a translatable conjugation platform should look like.
Real question is whether COX-2/EV silencing holds up in a fibroblast-rich, resistant tumor, not just a clean xenograft — but as a proof that microenvironment-directed degradation is maturing past a concept, this is convincing.
Receptor-Guided Targeted Protein Degradation Collapses Extracellular Vesicle-Driven Tumor-Stroma Crosstalk ↗
2026-09-17 · ⚗️Protein kinases — Catalytic Cluster Residues (conserved Lys/Asp/Glu in the ATP pocket) · Journal of Medicinal Chemistry (ACS)
- More than 300 X-ray cocrystal structures spanning diverse kinase-inhibitor complexes were analyzed to catalog recurring non-covalent contact patterns.
- The study highlights a set of conserved Lys, Asp, and Glu residues near the ATP pocket, dubbed "Catalytic Cluster Residues" (CCRs), that support catalysis and frequently contact bound inhibitors.
- Across most inhibitor chemotypes, these polar residues form non-covalent interactions rather than covalent bonds, making them broadly relevant handles for ligand design.
- Side-chain orientation of the CCRs tracks with the kinase's active or inactive conformational state, linking binding geometry to structural dynamics.
- The authors argue this conformation-coupled behavior can guide rational, structure-based inhibitor design aimed at improving potency and tuning selectivity across the kinome.
💡 Points"Catalytic Cluster Residues" is new branding for something most kinase chemists already lean on informally — the Lys-Glu ion pair, DFG-Asp contacts.
The real value here is systematizing it: 300+ structures gives a statistical backbone for deciding when to actually chase these polar contacts instead of hinge binding or a back-pocket selectivity vector.
If CCR geometry really tracks active/inactive state, that's a usable lever — bias type-I vs type-II engagement via salt bridges and H-bonds instead of reaching for a covalent warhead, attractive when cysteine liabilities or covalent reversibility are a concern.
I'm skeptical the conformational-coupling claim generalizes cleanly across the kinome, though — 300 structures sounds like a lot until you split it by subfamily, and PDB deposition bias means scaffolds like EGFR, ABL, and CDKs are almost certainly overrepresented relative to understudied kinases.
A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases ↗
2026-09-17 · ⚗️STING — small-molecule-induced degradation (repurposed Nrf2 activator, non-PROTAC mechanism) · Nature Communications (Nature)
- Omaveloxolone is an FDA-approved Nrf2-activating drug, originally approved for Friedreich's ataxia, now repurposed as a STING-targeting agent.
- It binds the base of STING's ligand-binding domain, destabilizing the protein's folded structure.
- This triggers K27-linked polyubiquitination of STING and its subsequent degradation by the proteasome — a "molecular crowbar" mechanism.
- Unlike classical PROTAC-style bifunctional degraders, omaveloxolone acts as a single small molecule, directly destabilizing STING rather than using a ligand-linker-E3-ligase construct.
- In aged mice, omaveloxolone treatment reduced STING-pathway-driven inflammation, a hallmark of age-related "inflammaging."
💡 PointsA monovalent degrader that's neither a classic PROTAC nor a molecular glue — that's the interesting bit. "Molecular crowbar" reads like marketing, but mechanistically it sounds like ligand-induced conformational destabilization exposing a degron: closer to hydrophobic-tag logic than E3-recruitment chemistry, no linker or ternary-complex engineering required. Chemically elegant, if it holds up.
The real draw is that omaveloxolone's safety and PK are already banked — repurposing means skipping a decade of tox work if this translates. But my triage instinct says this is serendipitous polypharmacology, not designed SAR; the Nrf2 pharmacophore was never built for STING's pocket. It's also secondary-sourced with no primary structural data yet — I'd want a co-crystal or HDX-MS confirming direct engagement before trusting the crowbar story over generic proteostasis stress.
Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation ↗
2026-09-16 · ⚗️HDAC4/HDAC7 (Class IIa) — selective small-molecule inhibitors · ACS Medicinal Chemistry Letters (ACS)
- HDAC4 and HDAC7 — two class IIa histone deacetylases with tissue-restricted expression — were recently identified as distinct transcriptional drivers of Th17 cell differentiation.
- Using the class IIa scaffold TMP269 as a starting point, researchers designed and synthesized a new series of HDAC4/7-targeted inhibitors.
- Structure-guided optimization of the metal-proximal and hydrophobic-binding regions yielded analogs with improved potency and greater isoform selectivity.
- Luciferase transcriptional assays, protein-binding studies, and docking analyses revealed distinct SAR patterns that separately govern selectivity for HDAC4 versus HDAC7.
- The resulting compounds offer selective chemical probes for dissecting HDAC4 and HDAC7 function in Th17 biology and a foundation for future therapies targeting Th17-driven inflammatory disease, including IBD.
💡 PointsClass IIa HDACs are pseudo-catalytic with shallow, promiscuous pockets — TMP269 already buys you pan-IIa selectivity over class I/IIb almost for free, so the real fight here is splitting HDAC4 from HDAC7, and that's the part I'd actually flag.
Their catalytic domains are near-identical; selectivity has to come from second-shell/rim contacts in the hydrophobic channel, not the zinc-binding group, so decoupling the metal-chelating SAR from the selectivity-driving SAR (as they describe) is the right strategy and not trivial to execute.
As probes, these look solid — potency plus genuine paralog discrimination is exactly what's needed to deconvolute Th17 phenotypes cleanly, though I'd want permeability/off-target data before trusting cellular calls.
Going after Th17/IBD instead of the usual oncology playground is the smarter long game too: pan-HDACi toxicity is a dealbreaker for chronic dosing, and isoform-restricted engagement is the only realistic path to a tolerable chronic immunomodulator.
Structure-Guided Development of Selective HDAC4 and HDAC7 Inhibitors That Modulate Th17 Cell Transcription ↗
2026-09-17 · 💻Keap1-Nrf2 PPI — virtual screening methodology/QC (co-folding + ML scoring cascade) · chemRxiv
- Multi-stage virtual screening cascades that combine AI co-folding models with learned-affinity (ML) scoring are now standard practice in computational drug discovery.
- Each stage's output score is typically taken at face value and used to advance or discard candidates without independent validation of what it actually captures.
- This preprint systematically evaluates, stage by stage, whether cascade scores provide the information practitioners need to trust them, using the Keap1-Nrf2 protein-protein interaction as a case-study target.
- The authors characterize failure modes that arise at different stages of the cascade, offering a quality-control perspective on where and why these pipelines can mislead.
💡 PointsEvery screening campaign now runs some flavor of co-fold-then-ML-score cascade, and honestly most of us take the ranked list at face value because checking each stage is a pain.
That's the exact habit this preprint is poking at, using Keap1-Nrf2 — a notoriously flat, shallow PPI interface that's already brutal for docking and pharmacophore methods — as a stress test where scoring artifacts should show up fast.
If the abstract's framing holds, the real message isn't "don't use these tools," it's "don't trust a single composite score without knowing what each stage is actually measuring" — pose confidence, affinity ranking, and physical plausibility are not the same thing, and conflating them is how false positives sneak to the top.
Worth revisiting once the full methodology and failure-mode breakdown are out; details here are still thin.
Per-Stage Controls and Failure Modes in a Co-Folding Virtual Screening Cascade for the Keap1–Nrf2 Interaction ↗
2026-09-16 · 💻Hit-finding platform / library design (case studies: trypanosomal CLK1, 14-3-3/ERα molecular glue, SARS-CoV-2 Mpro) · Journal of Chemical Information and Modeling (ACS)
- "Scope" describes a mid-sized (10k-50k compound) chemical space positioned between minimal fragments and fully elaborated low-molecular-weight libraries, designed to maximize ligand efficiency and medicinal chemistry tractability.
- The authors introduce "Scope ring systems" (ring-X-ring) as a core organizing concept for building libraries and guiding functionalization toward sufficient potency.
- A 10k-compound Scope screening set — evaluated by SPR, native mass spectrometry, DSF, and biochemical assays — matches general diversity sets' primary hit rates even at higher screening concentrations, while showing superior ligand efficiency and higher hit rates after counter-screening.
- Case studies on trypanosomal CLK1 kinase, a 14-3-3/estrogen receptor-alpha molecular glue project, and SARS-CoV-2 main protease show the set yields diverse, tractable, ligand-efficient hits across varied binding sites.
💡 PointsThe "sweet spot between fragments and full libraries" pitch isn't new — DEL, FBDD, and house libraries have all claimed it before. What's actually new in Scope is the ring-X-ring organizing logic: forcing vectors off two ring systems rather than one flat scaffold gives a built-in growth vector for SAR from hit one, the part fragment campaigns usually bolt on later.
The number that matters to me isn't the hit rate, it's "higher hit rate after counter-screening" — that's fewer SPR artifacts and aggregators wasting my week.
The real test is the 14-3-3/ERα glue case: PPI/glue targets chew up conventional libraries because there's no deep pocket to reward LE. If a rigid, moderately-sized scaffold set can seed a glue hit, that's the transferability claim worth watching, not the Mpro or CLK1 wins.
The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro ↗
2026-09-17 · 🏢Startup launch / pipeline progress · STAT News · Ariadne Bio
- Ariadne Bio launched as a spinout of Palomar Labs, with lead program AB-300 — a clinical-stage-ready, non-hallucinogenic serotonin 2A (5-HT2A) receptor agonist.
- AB-300 targets apathy in Parkinson's disease, a symptom affecting a significant share of patients that currently has no approved treatment; evidence suggests SSRIs can worsen it.
- The company is funded by Palomar Labs and a grant from The Michael J. Fox Foundation for Parkinson's Research, supporting a Phase 1b trial of AB-300 planned for the second half of 2026.
- Ariadne is the second neuropsychiatry startup founded by Shlomi Raz, following Eleusis, whose lineage (via Beckley Psytech and AtaiBeckley) led to an Eli Lilly acquisition agreement in July 2026.
💡 PointsAriadne is the latest entrant in the growing "psychedelic-like without the trip" race — biased 5-HT2A agonism is becoming the de-risking playbook that lets CNS developers chase serotonergic mechanisms while sidestepping hallucinogen stigma and REMS-heavy dosing; expect more spinouts to follow this template.
Smarter still is the indication choice: apathy has zero approved therapies and SSRIs can actively worsen it, so AB-300 sidesteps the saturated Parkinson's motor-symptom field entirely — a genuine white-space bet rather than a me-too.
Founder Shlomi Raz's Eleusis lineage (Beckley Psytech/AtaiBeckley → Lilly) is doing real work here too: it's a legible pattern for investors and future acquirers that this team can carry psychedelic-adjacent CNS assets to an exit.
The Michael J. Fox Foundation grant alongside Palomar's funding also signals disease-foundation money increasingly co-underwriting rare/niche CNS bets alongside VC capital.
New startup to test psychedelic-like drug against Parkinson's symptom ↗
2026-09-17 · 🏢Market access / reimbursement deal · STAT News · AstraZeneca / Daiichi Sankyo
- NICE, which sets drug-funding recommendations for NHS England, will fund Enhertu (trastuzumab deruxtecan) for HER2-low metastatic or unresectable breast cancer after chemotherapy, reversing a July 2024 rejection on cost grounds.
- The reversal follows a UK-US pharmaceutical pricing deal that led NICE to raise its cost-effectiveness threshold and revise its appraisal methodology, making some costlier innovative drugs newly reimbursable.
- Enhertu, an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo, has been reported in studies to meaningfully extend survival for this patient group versus chemotherapy alone, though the size of the benefit varies.
- An estimated 1,000 patients in England are expected to gain access, with treatment available within days of the decision.
💡 PointsNICE just permanently loosened its willingness-to-pay bar — as a negotiated line item in a bilateral trade deal, not a one-off cost-effectiveness review. That's the story here, not the roughly 1,000 patients gaining access: expect other governments squeezed between fiscal discipline and access pressure, and other pharma negotiators facing NICE, to point to this precedent.
For AstraZeneca and Daiichi Sankyo, it de-risks Enhertu's ex-US rollout playbook: reimbursement fights in other cost-constrained markets (Canada, Australia, parts of Europe) just got a stronger comparator to cite.
More broadly, this nudges the ceiling on what NICE will pay for high-cost ADCs and next-gen oncology assets generally, benefiting the wider oncology ADC pipeline queuing up for UK launch, not just this one drug.
Watch whether AZ/Daiichi price other Enhertu indications, or future ADCs, against this new threshold.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal ↗
2026-09-17 · 🏢Trial outlook / likely discontinuation signal · STAT News · Sellas Life Sciences
- GPS (galinpepimut-S), Sellas Life Sciences' cancer immunotherapy, is being tested in the Phase 3 REGAL trial in acute myeloid leukemia (AML) patients who are in a second remission after at least two prior lines of therapy.
- REGAL enrolled more than 100 patients; its primary endpoint is overall survival versus standard of care.
- The trial has an event-driven design requiring 80 patient deaths to trigger the final survival analysis; as of the latest count, 72 of the 80 required events had occurred.
- Completion has slipped nearly a year past original timelines — a pace a Sept. 17, 2026 STAT News analysis reads as concerning, since slower-than-expected death accrual can hint that a drug isn't extending survival as hoped.
- This failure prediction is informed analyst/columnist speculation based on trial mechanics and the delay pattern, not an official, sponsor-confirmed readout.
💡 PointsTrial-watchers read event-driven Phase 3s by the clock, not the topline: REGAL needs 80 deaths to unlock its survival readout, and sitting at 72/80 nearly a year behind schedule is the kind of pattern sophisticated observers flag as a soft signal, not a verdict.
Slower death accrual can mean GPS is genuinely extending survival — the optimistic read — but it's equally consistent with sluggish enrollment, extended follow-up, or censoring quirks unrelated to efficacy; event-driven mechanics are inherently ambiguous until the data actually locks.
What is real: this is a binary, pipeline-defining catalyst for a small-cap with limited depth beyond GPS in AML. A negative readout would sharply narrow strategic options — partnership leverage, cash runway, follow-on financing — while a positive one could be a rare re-rating story.
Until REGAL formally reads out, this remains informed speculation, not a confirmed result.
A Sellas immunotherapy study, long delayed, will end in failure ↗
2026-09-17 · 🏢FDA approval / pipeline milestone · STAT News · Ultragenyx
- The FDA granted full approval on September 17, 2026 to FAYUVI (rebisufligene etisparvovec-hopf, also known as UX111), an AAV-based gene therapy developed by Ultragenyx.
- FAYUVI is indicated for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome Type A — a progressive, fatal neurodegenerative disorder sometimes called "childhood Alzheimer's" that causes developmental delay followed by loss of cognitive, language, and motor function.
- It is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A and represents Ultragenyx's second approved gene therapy overall.
- The approval qualified Ultragenyx for a Priority Review Voucher.
- Commercial product is expected to begin shipping to Qualified Treatment Centers within 30 to 60 days.
💡 PointsSecond AAV gene therapy approval in Ultragenyx's stable is the real headline here — it validates a repeatable regulatory and manufacturing playbook for ultra-rare CNS disease, not a one-off. That de-risks the rest of the pipeline (other MPS subtypes, Angelman, etc.) in investors' eyes far more than the Sanfilippo indication itself.
The Priority Review Voucher is worth watching separately: PRVs have changed hands for $100M+ in recent years, so this is a monetizable balance-sheet asset Ultragenyx can sell or redeem, not just a regulatory footnote.
On revenue, ultra-rare gene therapies typically carry seven-figure list prices against a tiny diagnosed population — expect a slow, lumpy ramp gated by Qualified Treatment Center onboarding and payer negotiations rather than the 30-60 day shipping window.
No approved or late-stage competitor targets MPS IIIA specifically, so Ultragenyx effectively owns this niche outright — for now.
FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease ↗
2026-09-16 · 🏢Phase 2b trial failure / cost-cutting · Fierce Biotech · Longeveron
- Longeveron's Phase 2b ELPIS II trial tested laromestrocel, a mesenchymal stem cell therapy, as an add-on to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS), a rare, severe congenital heart defect.
- The trial missed its primary endpoint: at 12 months, right ventricular ejection fraction did not improve meaningfully in treated infants versus controls.
- No new safety signals emerged; treated infants had numerically fewer deaths than controls over 12 months — reassuring, but not a substitute for the missed efficacy signal.
- Following the miss, Longeveron said it will cut costs, is "exploring all options" for the program and company strategy, and plans further FDA discussions.
- Shares fell sharply in premarket trading after the announcement.
💡 PointsThis is another entry in cell therapy's uneven ledger: mesenchymal stem cell candidates have repeatedly stumbled in small, underpowered pediatric and rare-disease trials, and a 40-patient study was never going to generate a statistically bulletproof efficacy case either way.
The "numerically fewer deaths" framing is a familiar move — a directionally encouraging but non-significant number, worth reading as reassurance on safety, not as a rescue for the missed primary endpoint.
More telling is the language around cost cuts and "exploring all options": for a small-cap with a thin, concentrated pipeline built largely around laromestrocel, that's the standard prelude to a strategic pivot — partnering out remaining assets, a reverse merger, or a slow wind-down — rather than business as usual.
Investors should expect the MSC therapy category's credibility gap with capital markets to widen further on this news.
Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' ↗
2026-09-16 · 🏢M&A (reverse merger) / financing · Fierce Biotech · North Immunology / Aethlon Medical
- North Immunology, incubated for two years inside hedge fund ADAR1 Capital Management, is going public via a reverse merger with Nasdaq-listed Aethlon Medical, trading as North Immunology under new ticker "NRTX"; Aethlon holders keep about 4.75%.
- Lead asset NOR-101 is a half-life-extended bispecific antibody targeting IL-13 and IL-18, being developed for atopic dermatitis (eczema) as a potential next-generation competitor to Dupixent.
- The deal includes a $180 million PIPE financing from investors such as Bain Capital, Janus Henderson, and Deep Track Capital, funding operations into the second half of 2028.
- Phase 1a is planned for early 2027, with interim PK/safety data by mid-2027 and Phase 1b/2b topline results in 2028.
💡 PointsThe reverse-merger-plus-PIPE playbook is becoming the default exit ramp for well-capitalized private biotechs in a still-tepid IPO market — expect more of these Nasdaq-shell conversions through 2026 as sponsors sidestep the pricing risk of a traditional roadshow.
More interesting is the origin story: ADAR1 Capital incubating NOR-101 in-house for two years before spinning it out is a hedge fund acting like a venture creator, not just a stock-picker — a build-then-monetize model worth watching as more crossover funds chase asset-level returns.
Going after IL-13/IL-18 dual blockade puts North squarely in Dupixent's shadow; differentiated mechanism aside, atopic dermatitis is already crowded (Amgen's rocatinlimab, Sanofi/Regeneron's own follow-ons), so competitive execution and pricing power at launch will matter more than novelty.
With Phase 1a not starting until 2027, there's no near-term catalyst — this is a story investors have to hold through, not trade around.
North Immunology goes public via reverse merger as eczema drug heads toward clinic ↗
2026-09-16 · 🏢Financing / pipeline progress · Fierce Biotech · Sling Therapeutics
- Sling Therapeutics closed a $123 million Series C led by Forbion, joined by existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management.
- Proceeds will fund Phase 3 development of linsitinib, Sling's oral small-molecule IGF-1R inhibitor, for thyroid eye disease (TED).
- Unlike IV monoclonal antibodies that bind IGF-1R directly, such as Amgen's Tepezza and Viridian's Lumvoa, linsitinib is taken orally and affects IGF-1R phosphorylation, offering a potentially safer, more durable, more convenient option.
- Sling has begun dosing patients in its global pivotal Phase 3 ORBIT trial in moderate-to-severe active TED, building on its completed Phase 2b/3 LIDS trial, which met its efficacy goal.
- The financing positions Sling to compete against an established blockbuster IV therapy market for TED.
💡 PointsTepezza is a multi-billion-dollar franchise that helped justify Amgen's $27.8B Horizon Therapeutics acquisition — so an oral challenger here isn't just chasing an indication, it's chasing the economics that made that deal work.
Forbion leading a $123M round through Phase 3, with TPG re-upping and Sectoral joining fresh, signals real conviction in the differentiation thesis itself, not just TED as a hot category.
The commercial logic is straightforward: IV infusions carry site-of-care burden, scheduling friction, and infusion-reaction risk that a pill sidesteps — real value in a chronic, relapsing disease where compliance matters.
But incumbents hold prescriber relationships and entrenched reimbursement pathways; an oral entrant more likely peels off infusion-averse or relapsed patients first than displaces frontline share outright, unless Phase 3 data show a decisive edge.
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial ↗